This is supported by the finding that pre-symptomatic FTD causing mutant MAPT carriers had intermediate levels of brain atrophy compared to symptomatic carriers but comparable glucose hypometabolism (Deters et al., 2014). The gene discussed is MAPT; the disease is frontotemporal dementia.